|
Ronald Bowsher, Ph.D. is Vice-President and Chief Scientific Officer at LINCO Diagnostic Services, Inc. located in St. Charles, Missouri. In addition, he is a partner in the data analysis and statistical consulting company, Bowsher Brunelle Smith, LLC and a Fellow of the American Association of Pharmaceutical Sciences. Prior to joining LINCO Diagnostic Services in 2003, Dr. Bowsher retired after 30 years at the Lilly Research Laboratories. His primary research interest has been the development and validation of immunoassays and related technologies for the bioanalysis of biopharmaceuticals, biomarkers, conventional small molecule drugs and anti-drug antibodies to support GLP-compliant assessments of drug pharmacokinetics, pharmacodynamics and safety. While at Lilly, he led bioanalytical research groups responsible for preclinical and clinical development of protein therapeutics, clinical biomarkers and clinical immunogenicity. He is particularly recognized for his scientific contributions to the development of improved immunoanalytic methods for quantitative determination of human insulin, insulin analogs and other biosynthetic proteins in biological matrices. Some of the marketed products supported by Dr. Bowsher include Humulin (insulin), Humalog (insulin lispro), Permax, Evista, Forteo� (PTH1-34), Humatrope (hGH) and Xigris (rAPC). In addition, he has published nearly 200 research papers, abstracts and has two patents and has spoken frequently on validation of assays for biopharmaceuticals and novel biomarkers. In 2001, he founded and organized the Ligand Binding Assay Bioanalytical Focus Group within AAPS to create a forum to address issues, seek harmonization and promote education for the development, validation and application of analytical methods for the bioanalysis of small molecules, biopharmaceuticals and biomarkers by binding assay technologies. Dr. Bowsher is the 2006 Past-Chair of the AAPS Biotechnology Section. | 